Technical Analysis for GBT - Global Blood Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
62.33 | 6.11% | 3.59 |
GBT closed up 6.11 percent on Wednesday, April 8, 2020, on 1.18 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Historical GBT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/06/2020
- Sector: Healthcare
- Industry: Biotechnology
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in double-blind Phase I/II clinical trial indicated for the treatment of sickle cell disease. The company also focuses on developing an oral prophylactic therapy for hypoxemic pulmonary disorders and hereditary angioedema. The company was founded in 2011 and is based in South San Francisco, California.
Medicine Biopharmaceutical Medical Specialties Blood Sickle Cell Disease Hereditary Angioedema Angioedema Hemoglobin Hemoglobins
Medicine Biopharmaceutical Medical Specialties Blood Sickle Cell Disease Hereditary Angioedema Angioedema Hemoglobin Hemoglobins
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 87.54 |
| 52 Week Low | 39.95 |
| Average Volume | 911,295 |
| 200-Day Moving Average | 59.18 |
| 50-Day Moving Average | 60.82 |
| 20-Day Moving Average | 50.45 |
| 10-Day Moving Average | 53.67 |
| Average True Range | 5.08 |
| ADX | 25.28 |
| +DI | 26.47 |
| -DI | 15.89 |
| Chandelier Exit (Long, 3 ATRs ) | 48.63 |
| Chandelier Exit (Short, 3 ATRs ) | 55.18 |
| Upper Bollinger Band | 60.43 |
| Lower Bollinger Band | 40.48 |
| Percent B (%b) | 1.1 |
| BandWidth | 39.55 |
| MACD Line | -0.86 |
| MACD Signal Line | -2.96 |
| MACD Histogram | 2.0981 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 71.14 | ||||
| Resistance 3 (R3) | 70.39 | 66.71 | 69.67 | ||
| Resistance 2 (R2) | 66.71 | 64.46 | 67.08 | 69.18 | |
| Resistance 1 (R1) | 64.52 | 63.08 | 65.61 | 65.27 | 68.69 |
| Pivot Point | 60.83 | 60.83 | 61.38 | 61.21 | 60.83 |
| Support 1 (S1) | 58.64 | 58.59 | 59.74 | 59.39 | 55.97 |
| Support 2 (S2) | 54.96 | 57.20 | 55.33 | 55.48 | |
| Support 3 (S3) | 52.77 | 54.96 | 54.99 | ||
| Support 4 (S4) | 53.52 |
